Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Treats relapsing forms of multiple sclerosis (MS). Sold as Mayzent. Every FDA application for this active ingredient: 1 branded and 4 generic.
As of Nov 14, 2026, FDA lists 5 applications for Siponimod (sold as Mayzent), first approved Mar 26, 2019, with 1 new use approved and 0 published complete response letters.
First approved: Mar 26, 2019
Applications: 5
New uses approved: 1
Complete response letters: 0
Medicare spending, 2025: $76.9M
First approved in the EU: Jan 13, 2020
Medicare Spending
CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient.Drugs@FDA
Novartis
Cipla